Clinical Trials Data Policy Therapy 
Veriheal
JUNE 30, 2023
A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.
Cannabis Law Report
JANUARY 12, 2022
Today, Maya (Maya PBC) and the National Psychedelics Association (NPA) announced their partnership in support of the implementation of Oregon’s Measure 109, the first state-approved policy to allow the regulated use of psilocybin products in a facilitated setting.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 29, 2022
FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. More recently, MDMA therapy has inched closer to FDA approval. Clinical Trials and Human Subject Protections.
Cannabis Law Report
NOVEMBER 15, 2021
PCR-produced LinearDNA serves as a pure, fast, and flexible alternative to plasmid DNA (pDNA) in the manufacture of cell and gene therapies (CGTs) and nucleic acid vaccines. CRO orders typically provide a means to evaluate LinearDNA within a customer’s preclinical development program. News release. FDA website. January 15, 2019. 2021.08.006.
Cannabis Law Report
NOVEMBER 19, 2021
MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.
The Cannigma
AUGUST 31, 2021
A 2018 research paper in the International Journal of Drug Policy analyzed in-depth interviews carried out with 24 Israeli physicians working in pain medicine, oncology, and family medicine, and found that “physicians discussed contrasting narratives of cananbi, presenting it as both a medicine and non-medicine.”
Canna Law Blog
NOVEMBER 6, 2021
But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Instead, qualifying evidence may come from adequate and well-controlled clinical trials. Phase I trials should be sufficient, and many have been completed using psilocybin.
Expert insights. Personalized for you.
98 
Let's personalize your content